Replies to post #114539 on Biotech Values

[mcbio]

What are your feeling regarding M118 after todays conference call?

I thought Wheeler was still fairly upbeat about the program. I believe the specific line during planned remarks was something along the lines of "we remain invested in M118's continued development." There was some key discussion around the 48 minute mark during Q&A though. Wheeler indicated that partnering in the cardio market looks better today. He also indicated that MNTA has initiated a new round of discussions for partnering M118.

[DewDiligence]

What are your feelings regarding M118 after today’s conference call?

My view of the M118 program is unchanged—see #msg-57621347. I hope I’m wrong, of course.

It’s now been 17 months since MNTA announced results of the phase-2 EMINENCE study (#msg-41846746). Drugs with large commercial potential rarely if ever lie fallow for that long.